![WuXi AppTec Co., Ltd. Website](https://cdn.finchat.io/37259571.png)
WuXi AppTec Co., Ltd.
SHSE-603259
Company Overview
WuXi AppTec Co., Ltd., an investment holding company, provides research, development, and manufacturing services to discover, develop, and manufacture small molecule drugs, and cell and gene therapies in the People's Republic of China, rest of Asia, the United States, Europe, and internationally. The company operates through six segments: WuXi Chemistry, WuXi Testing, WuXi Biology, WuXi ATU, WuXi DDSU, and Others. It offers contract research, development, and manufacturing organization services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions that support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides seamless drug and medical device testing services from preclinical testing to clinical trials; an integrated end-to-end solution to accelerate time to market for cell and gene therapies; drug discovery services to pharmaceutical and biotech customers; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.
Name
WuXi AppTec Co., Ltd.
CEO
Dr. Ge Li Ph.D.
Website
www.wuxiapptec.com
Sector
Life Sciences Tools and Services
Year Founded
2000
Profile
Market Cap
CN¥110.14B
EV
CN¥103.02B
Shares Out
2,911.93M
Revenue
CN¥38.71B
Employees
38,134
Margins
Gross
40.77%
EBITDA
31.47%
Operating
26.02%
Pre-Tax
27.09%
Net
22.04%
FCF
21.04%
Returns (5Yr Avg)
ROA
10.97%
ROTA
16.29%
ROE
15.66%
ROCE
14.89%
ROIC
13.56%
Valuation (TTM)
P/E
—
P/B
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
EV/Gross Profit
—
Valuation (NTM)
Price Target
CN¥58.36
P/E
—
PEG
—
EV/Sales
—
EV/EBITDA
—
P/FCF
—
Financial Health
Cash
CN¥14.67B
Net Debt
-CN¥7,505.93M
Debt/Equity
0.13
EBIT/Interest
45.49
Growth (CAGR)
Rev 3Yr
24.96%
Rev 5Yr
28.38%
Rev 10Yr
—
Dil EPS 3Yr
29.05%
Dil EPS 5Yr
30.14%
Dil EPS 10Yr
—
Rev Fwd 2Yr
3.62%
EBITDA Fwd 2Yr
4.65%
EPS Fwd 2Yr
6.93%
EPS LT Growth Est
6.45%
Dividends
Yield
—
Payout
33.89%
DPS
CN¥0.99
DPS Growth 3Yr
48.46%
DPS Growth 5Yr
32.04%
DPS Growth 10Yr
—
DPS Growth Fwd 2Yr
3.39%